These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2698 related articles for article (PubMed ID: 28444290)

  • 41. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
    Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
    JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM.
    Langlois MR; Nordestgaard BG; Langsted A; Chapman MJ; Aakre KM; Baum H; Borén J; Bruckert E; Catapano A; Cobbaert C; Collinson P; Descamps OS; Duff CJ; von Eckardstein A; Hammerer-Lercher A; Kamstrup PR; Kolovou G; Kronenberg F; Mora S; Pulkki K; Remaley AT; Rifai N; Ros E; Stankovic S; Stavljenic-Rukavina A; Sypniewska G; Watts GF; Wiklund O; Laitinen P;
    Clin Chem Lab Med; 2020 Mar; 58(4):496-517. PubMed ID: 31855562
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of hypercholesterolemia for prevention of atherosclerotic cardiovascular disease: focus on the potential role of recombinant anti-PCSK9 monoclonal antibodies.
    Verma DR; Brinton EA
    Rev Cardiovasc Med; 2014; 15(2):86-101; quiz 101. PubMed ID: 25051126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India.
    Puri R; Mehta V; Duell PB; Nair D; Mohan JC; Yusuf J; Dalal JJ; Mishra S; Kasliwal RR; Agarwal R; Mukhopadhyay S; Wardhan H; Khanna NN; Pradhan A; Mehrotra R; Kumar A; Puri S; Muruganathan A; Sattur GB; Yadav M; Singh HP; Agarwal RK; Nanda R
    J Clin Lipidol; 2020; 14(2):e1-e13. PubMed ID: 32089456
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
    Navarese EP; Robinson JG; Kowalewski M; Kolodziejczak M; Andreotti F; Bliden K; Tantry U; Kubica J; Raggi P; Gurbel PA
    JAMA; 2018 Apr; 319(15):1566-1579. PubMed ID: 29677301
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Role of Statins in Current Guidelines.
    Rached F; Santos RD
    Curr Atheroscler Rep; 2020 Aug; 22(9):50. PubMed ID: 32770357
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?
    Zhou R; Stouffer GA; Smith SC
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):533-549. PubMed ID: 34138676
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Keep recycling going: New approaches to reduce LDL-C.
    Klein-Szanto AJP; Bassi DE
    Biochem Pharmacol; 2019 Jun; 164():336-341. PubMed ID: 30953636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
    Reiner Ž
    Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cholesterol-Lowering Agents.
    Rosenson RS; Hegele RA; Koenig W
    Circ Res; 2019 Feb; 124(3):364-385. PubMed ID: 30702994
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Childhood Non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events.
    Wu F; Juonala M; Jacobs DR; Daniels SR; Kähönen M; Woo JG; Sinaiko AR; Viikari JSA; Bazzano LA; Burns TL; Steinberger J; Urbina EM; Venn AJ; Raitakari OT; Dwyer T; Magnussen CG
    Circulation; 2024 Jan; 149(3):217-226. PubMed ID: 38014550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
    ; Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
    J Am Coll Cardiol; 2016 Jul; 68(1):92-125. PubMed ID: 27046161
    [No Abstract]   [Full Text] [Related]  

  • 54. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
    O'Keefe JH; DiNicolantonio JJ; Lavie CJ
    Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
    Wadström BN; Wulff AB; Pedersen KM; Nordestgaard BG
    Curr Atheroscler Rep; 2023 Nov; 25(11):795-803. PubMed ID: 37768410
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum Low-Density Lipoprotein Cholesterol and Cardiovascular Disease Risk Across Chronic Kidney Disease Stages (Data from 1.9 Million United States Veterans).
    Hashemi L; Hsiung JT; Arif Y; Soohoo M; Jackson N; Gosmanova EO; Budoff M; Kovesdy CP; Kalantar-Zadeh K; Streja E
    Am J Cardiol; 2022 May; 170():47-55. PubMed ID: 35300833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. What should be the goal of cholesterol-lowering treatment? A quantitative evaluation dispelling guideline myths.
    Durrington PN; Bashir B; Soran H
    Curr Opin Lipidol; 2022 Aug; 33(4):219-226. PubMed ID: 36082945
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Approach to the Patient With a Suboptimal Statin Response: Causes and Algorithm for Clinical Management.
    Sun L; Wolska A; Amar M; Zubirán R; Remaley AT
    J Clin Endocrinol Metab; 2023 Aug; 108(9):2424-2434. PubMed ID: 36929838
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 135.